Yazar "Eren, Rafet" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Charlson comorbidity index (CCI) in diffuse large B-cell lymphoma: a new pproach in a multicenter study
    (Springer, 2022) Eren, Rafet; Serin, İstemi; Atak, Süheyla; Pirdal, Betül Zehra; Nizam, Nihan; Gemici, Aliihsan; Aydın, Demet; Demirel, Naciye; Doğan, Esma Evrim; Yokuş, Osman
    Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment. Patients often have difficulty tolerating standard chemotherapy regimens due to their comorbidities. Charlson Comorbidity Index (CCI), which is calculated by considering 19 different comorbidities, was developed in 1987 and is widely used for mortality prediction in cancer patients. Literature data on CCI and hematological malignancies are limited. Main aim in this study is to evaluate the effectiveness of CCI and compare to the International Prognostic Index (IPI) scoring system in the DLBCL patient group. Methods: A total of 170 patients diagnosed with DLBCL between 1.1.2002- 1.12.2020 were included in the study. Statistical analyzes were performed among patients whose IPI and CCI scores were recorded by considering baseline data. Results: The median age of patients was 58 (range: 17–84). Thirty-five (20.6%) patients had stage III and 76 (44.7%) had stage IV disease. When the CCI, IPI and ECOG scores were compared with the mortality status of the patients as a reference, AUCs were resulted as 0.628 (95% CI: 0.506–0.749), 0.563 (95% CI: 0.484–0.639) and 0.672 (95% CI: 0.596–0.743), respectively. There was no significant difference between the ROC curves of CCI, IPI and ECOG scores. Patients with a CCI score of ? 4 had shorter OS comperad to those with a score of < 4. Conclusion: Rather than claiming that CCI is superior to IPI, ECOG or another scoring system in a single-center patient population, it should be stated that CCI is also an effective scoring system in patients diagnosed with DLBCL.
  • Küçük Resim
    Öğe
    Evaluation of the relationship between bone marrow changes and hemogram findings in HIV-positive patients
    (Galenos publ house, 2025) Karışmaz, Abdulkadir; Cavdar, Vahit Can; Doğu, Mehmet Hilmi; Aslan, Ceyda; Sarı, Nagehan Didem; Erdem Huq, Gülben; Eren, Rafet
    Aim: This study aimed to evaluate the relationship between bone marrow (BM) changes and initial laboratory findings in Human immunodeficiency virus (HIV)-positive patients, focusing on hematopoietic system alterations such as myeloid hyperplasia, erythroid hyperplasia, and megakaryocyte activity. Materials and Methods: A total of 57 HIV-positive patients were included in this retrospective study. BM findings, including cellularity, plasma cell ratio, reticulin fiber ratio, and specific features such as myeloid and erythroid hyperplasia, were analyzed. Initial laboratory parameters, including white blood cell (WBC), hemoglobin (HGB), hematocrit (HCT), platelet, and CD4 counts, were assessed. Results: Significant positive correlations were observed between cellularity and WBC (r=0.40, p=0.005), monocyte (r=0.40, p=0.005), and CD8 counts (r=0.32, p=0.02). Plasma cell ratio showed negative correlations with HGB (r=-0.35, p=0.01), HCT (r=-0.35, p=0.01), and albumin (ALB) (r=-0.50, p<0.001). Reticulin fiber ratio was negatively correlated with WBC (r=-0.30, p=0.03), HGB (r=-0.32, p=0.02), and ALB (r=-0.35, p=0.008). Conclusion: BM changes in HIV-positive patients, such as myeloid and erythroid hyperplasia, are associated with significant alterations in peripheral blood parameters, highlighting the importance of comprehensive hematological evaluations in this population. These findings contribute to a better understanding of HIV-related hematopoietic dysfunction and its clinical implications
  • Küçük Resim
    Öğe
    Follicular lymphoma: frequency and timing of treatment: single center experience
    (Galenos publishing house, 2025) Karışmaz, Abdulkadir; Can Cavdar, Vahit; Serin, İstemi; Doğu, Mehmet Hilmi; Aslan, Ceyda; Eren, Rafet
    Introduction: This study aimed to investigate how often follicular lymphoma (FL) occurs in patients diagnosed with non-Hodgkin lymphoma (NHL). Additionally, we investigated whether patients with FL required treatment, and if so, whether the need for treatment arose at the initial diagnosis or during subsequent follow-up periods. Methods: Six thousand five hundred sixty patients diagnosed with NHL or chronic lymphocytic leukemia were reached, and healthy data were obtained from 1,719 of them. Data from 176 patients diagnosed with FL were evaluated. Demographic information (age, gender) of the patients was collected. The classifications were grouped by taking into account World Health Organization data, the histological subtype of the tumor, gender and need for treatment were evaluated. Results: Among the patients, 55.1% (n=97) were men and 44.9% (n=79) were women. The median age of those with FL was 50 years, with ages ranging from 18 to 87. When looking at histological subtypes, the FL accounts for 10.2% of cases (n=176). The proportion of patients requiring treatment was 70.9% (125), and the proportion of patients followed up without treatment was 27.8% (49). Of the patients who needed treatment, 57.1% (n=101) required it at the time of diagnosis and 13.6% (n=24) during follow-up. Conclusion: FL, making up around 20% of all NHL, is the second most prevalent type of lymphoma in adults. The incidence, as well as the gender and age distribution, of FL can differ across populations. This may be related to ethnicity, geographical conditions, and socioeconomic status. In addition, the proportion of patients requiring treatment may also vary. When all these are taken into account, social differences are some of the main determinants in the approach to FL.